Provided by Tiger Trade Technology Pte. Ltd.

Incyte

110.89
-2.5500-2.25%
Volume:698.15K
Turnover:77.67M
Market Cap:22.48B
PE:14.13
High:113.65
Open:112.89
Low:110.08
Close:113.44
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.70
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.54
PE(LYR):17.30

Loading ...

Incyte EVP, Chief Scientific Officer Patrick Mayes Sells 2,207 Shares for $273,447.93

Reuters
·
Aug 08

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Aug 07

Incyte’s EXCALIBUR-ET2 Trial Targets a New Edge in Essential Thrombocythemia

TIPRANKS
·
Aug 07

Top Incyte Insiders Quietly Cash In On Major Stock Sale

TIPRANKS
·
Aug 05

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Incyte EVP, Chief Scientific Officer Patrick Mayes Disposes of Shares Worth $5.32 Million

Reuters
·
Aug 05

Incyte price target raised to $137 from $121 at Mizuho

TIPRANKS
·
Aug 04

Mizuho Securities Remains a Buy on Incyte (INCY)

TIPRANKS
·
Aug 03

Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating

MT Newswires Live
·
Aug 03

Incyte Price Target Maintained with a $150.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 03

Incyte price target raised to $155 from $131 at Leerink

TIPRANKS
·
Aug 03

Incyte : Leerink Partners Raises Target Price to $155 from $131

THOMSON REUTERS
·
Aug 03

Incyte Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 01

Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating

MT Newswires Live
·
Jul 31

Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.
·
Jul 31

JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating

MT Newswires Live
·
Jul 30

Amneal Q2 Revenue Beats on Specialty Segment Growth

Reuters
·
Jul 30

Incyte Corp. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 30

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Reuters
·
Jul 30

Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says

MT Newswires Live
·
Jul 30